Latest blog articles
-
The 1st of April 2024 marks the day when Germany adopted the most progressive legal approach to cannabis in Europe. While for the Dutch, this may sound like an April’s fool prank, it is far from it: The new German CanG (Cannabis Law) regulates the consumption, possession, and supply of the soft drug...
-
The IMCO Committee is trying to amend the Unfair Commercial Practices Directive (2005/29) to include a ban on dark patterns. The proposed amendments are part of the EU’s plans to empower consumers for the green transition and the Parliament is expected to address the proposed amendments on 17 April...
-
Over the weekend of March 25-26, TikTok users started sharing videos of their experiences trying to delete their Instagram accounts on Android devices. Users took issue with not being able to delete their accounts via the Instagram app and having to use a desktop/mobile browser to complete the...
-
In early 2021, Europe’s twelve leading football clubs joined hands to create the European Super League. Despite the presence of notable clubs such as Liverpool, Manchester United, Milan, Barcelona and Real Madrid, the League soon fell apart. Unable to convince those on the football field, the three...
-
Germany has elected a new government. One of the legal reforms coalition of Social democrats, the Green party and the free liberals want to put on the tracks is the legalization of cannabis. From a criminological point of view, this is the right decision.
-
How do we guarantee access to COVID-19 vaccines and therapies, and secure health-related human rights for all? We’ve heard a string of promises in the race for new vaccines and therapies.
-
It’s been almost a month since the COVID-19 pandemic has drastically changed the way we live and work. Now that we are more used to, in a manner of speaking, the extraordinary measures to curtail the rampant spread of the virus, it’s time to seriously consider, and openly discuss, this crisis’...
-
Globally the majority of health-related R&D is invested in medicines with substantial guaranteed returns, yet what is missing is extensive R&D targeted at diseases overwhelmingly prevalent in developing countries. This threatens long-term availability of medicines and treatment options for these...